Harmony Biosciences (HRMY) Tops Q4 EPS by 44c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $1.01, $0.44 better than the analyst estimate of $0.57. Revenue for the quarter came in at $128.31 million versus the consensus estimate of $127.65 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
• Is the global equity rally broadening? UBS weighs in